The data presented in this study demonstrate that pharmacologic blockade of FLAP significantly reduces brain Aβ formation and deposition in the Tg2576 mouse model of AD, and thereby provide the first evidence that this protein is a novel therapeutic target for modulating amyloidogenesis in vivo. This evidence concerns the gene ALOX5AP and Alzheimer disease.